The design and synthesis of several classes of oligonucleotide analogs (OAs) incorporating improved, achiral, non-ionic phosphate linker surrogates are reported. Specifically, the synthesis and properties of monomers and oligomers based on five such linkers will be described, including lipophilic linkers based on various dialkylsiloxane moieties, especially diisopropylsiloxane; two moderately polar linkers (carboxylate ester and carboxamide) based on the appropriately 3'-substituted (hydroxy and amino), 5'-doubly-homologated nucleoside carboxylic acids; and polar surrogates (sulfonate esters and amides) prepared from the 3'-substituted, 5'-homologated nucleoside sulfonic acids. The potential advantages of oligonucleotides bearing non-ionic backbone linkages as clinical therapeutic agents are briefly discussed.The enormous potential of antisense oligonucleotide analogs (OAs) for the treatment of disease has elicited great excitement among medicinal chemists, who are intrigued by their promise of high specificity and broad applicability. The major goal of this strategy is to inhibit gene expression by interference with the transcription, translation, or replication of a given gene, through complementary (normally Watson-Crick) hybridization between the target (sense) and OA (antisense) strands. This interest has prompted extensive research designed to improve the stability, bioavailability, and potency of OAs. Our interest in this area arose from the observation that the current generation of OAs suffered from several shortcomings that might ultimately preclude their introduction as clinically useful agents. Thus, antisense compounds composed of natural DNA or RNA sequences suffer from rapid enzymatic degradation and poor uptake; DNA analogs based on the phosphorothioate linker, while of improved stability, nonetheless are charged, resulting in inefficient cellular membrane permeability and rapid clearance from the plasma, and chiral, which can cause intractable purification problems; and methylphosphonates, though uncharged, still suffer from the chirality drawback and typically display low potency. It was our belief that useful drugs would emerge only through the use of achiral, non-ionic OAs (NOAs). Consequently, we embarked upon a program of design and synthesis to